Hormone replacement therapy and risk of hip fracture: population based case-control study

Abstract Objective: To determine the relative risk of hip fracture associated with postmenopausal hormone replacement therapy including the effect of duration and recency of treatment, the addition of progestins, route of administration, and dose. Design: Population based case-control study. Setting: Six counties in Sweden. Subjects: 1327 women aged 50-81 years with hip fracture and 3262 randomly selected controls. Main outcome measure: Use of hormone replacement therapy. Results: Compared with women who had never used hormone replacement therapy, current users had an odds ratio of 0.35 (95 % confidence interval 0.24 to 0.53) for hip fracture and former users had an odds ratio of 0.76 (0.57 to 1.01). For every year of therapy, the overall risk decreased by 6% (3% to 9%): 4% (1% to 8%) for regimens without progestin and 11% (6% to 16%) for those with progestin. Last use between one and five years previously, with a duration of use more than five years, was associated with an odds ratio of 0.27 (0.08 to 0.94). After five years without hormone replacement therapy the protective effect was substantially diminished (7% to 48%). With current use, an initiation of therapy nine or more years after the menopause gave equally strong reduction in risk for hip fracture as an earlier start. Oestrogen treatment with skin patches gave similar risk estimates as oral regimens. Conclusions: Recent use of hormone replacement therapy is required for optimum fracture protection, but therapy can be started several years after the menopause. The protective effect increases with duration of use, and an oestrogen-sparing effect is achieved when progestins are included in the regimen. Key messages Hormone replacement therapy should be continued for long periods for optimal protection of hip fracture No overall substantial hip fracture protection remains after five years without hormone replacement therapy Therapy can be initiated several years after menopause without loss of fracture protection Oral or transdermal therapy are equally effective in reducing the risk of hip fracture The addition of progestins permits lower doses of oestrogens

[1]  H. Orimo,et al.  [Involutional osteoporosis]. , 1991, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics.

[2]  S Capewell,et al.  The continuing rise in emergency admissions , 1996, BMJ.

[3]  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. , 1996, JAMA.

[4]  H. Genant,et al.  The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. , 1996, JAMA.

[5]  S. Cummings,et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women , 1992, Annals of internal medicine.

[6]  J. Gallagher,et al.  Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. , 1991, The American journal of medicine.

[7]  T. Delbanco,et al.  Incidence and characteristics of preventable iatrogenic cardiac arrests. , 1991, JAMA.

[8]  Jane Smith.  Consultants of the future , 1995, BMJ.

[9]  C. Franklin,et al.  Developing strategies to prevent inhospital cardiac arrest: Analyzing responses of physicians and nurses in the hours before the event , 1994, Critical care medicine.

[10]  N. Weiss,et al.  Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. , 1980, The New England journal of medicine.

[11]  R. Rizzoli,et al.  Hormones and bones , 1997, The Lancet.

[12]  M. Mcnicol,et al.  Rethinking Consultants: Alternative models of organisation are needed , 1995, British medical journal.

[13]  R. Elkeles,et al.  Attitudes of consultant physicians to the Calman proposals: a questionnaire survey , 1995, BMJ.

[14]  S. Cummings,et al.  Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. , 1995, Annals of internal medicine.

[15]  R H Brook,et al.  Preventable deaths: who, how often, and why? , 1988, Annals of internal medicine.

[16]  O. Johnell,et al.  Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. , 1992, BMJ.

[17]  J. H. Cohen.  The Penguin Dictionary of Quotations , 1986 .

[18]  H. Adami,et al.  Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. , 1990, Annals of internal medicine.

[19]  L. Holmberg,et al.  Diet and hip fracture risk: a case-control study. Study Group of the Multiple Risk Survey on Swedish Women for Eating Assessment. , 1995, International journal of epidemiology.

[20]  R P Heaney,et al.  Calcium in the prevention and treatment of osteoporosis , 1992, Journal of internal medicine.

[21]  T Delamothe,et al.  Wanted: guidelines that doctors will follow. , 1993, BMJ.

[22]  H. Larsen,et al.  Better postural balance in elderly women receiving estrogens. , 1997, American journal of obstetrics and gynecology.

[23]  C. Cooper,et al.  Epidemiology of osteoporosis. , 2002, Best practice & research. Clinical rheumatology.

[24]  M. Charlson,et al.  Medical patients at high risk for catastrophic deterioration. , 1987, Critical care medicine.

[25]  A. Lane,et al.  Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen , 1992, Annals of Internal Medicine.

[26]  P. Burckhardt.  [Calcium in the prevention and treatment of osteoporosis]. , 1991, Therapeutische Umschau. Revue therapeutique.

[27]  D. Kiel,et al.  Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. , 1987, The New England journal of medicine.

[28]  C. Christiansen,et al.  Bone mass and its relationship to age and the menopause. , 1987, The Journal of clinical endocrinology and metabolism.

[29]  K. Hillman,et al.  Do nurses know when to summon emergency assistance? , 1994, Intensive & critical care nursing.

[30]  M. Stoneham,et al.  Knowledge about pulse oximetry among medical and nursing staff , 1994, The Lancet.

[31]  R. Lindsay,et al.  The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss , 1984, Obstetrics and gynecology.

[32]  D. Kiel,et al.  The effect of postmenopausal estrogen therapy on bone density in elderly women. , 1993, The New England journal of medicine.

[33]  S. Cummings,et al.  Heterogeneity of age-related fractures: implications for epidemiology. , 1987, Bone and mineral.

[34]  M. Hammar,et al.  Effects of Hormonal Replacement Therapy on the Postural Balance Among Postmenopausal Women , 1996, Obstetrics and gynecology.

[35]  A. E. Sheldon.  Effect of estrogen dose in postmenopausal bone loss. , 1984, The New England journal of medicine.

[36]  E. Barrett-Connor,et al.  Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. , 1997, JAMA.

[37]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.

[38]  N J Harper,et al.  Ability of hospital doctors to calculate drug doses , 1995, BMJ.

[39]  C. Christiansen,et al.  UNCOUPLING OF BONE FORMATION AND RESORPTION BY COMBINED OESTROGEN AND PROGESTAGEN THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS , 1985, The Lancet.

[40]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[41]  J. Prior.  Progesterone as a bone-trophic hormone. , 1990, Endocrine reviews.

[42]  R. Francis,et al.  The Effect of Estrogen Dose on Postmenopausal Bone Loss , 1983 .